Spark Therapeutics (NASDAQ: ONCE) recently received a number of ratings updates from brokerages and research firms:

  • 10/10/2017 – Spark Therapeutics had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $94.00 price target on the stock.
  • 10/10/2017 – Spark Therapeutics had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $95.00 price target on the stock.
  • 10/10/2017 – Spark Therapeutics had its “buy” rating reaffirmed by analysts at Cowen and Company. They now have a $95.00 price target on the stock. They wrote, “The FDA’s briefing documents appear mostly benign with most discussion centered.””
  • 10/10/2017 – Spark Therapeutics was given a new $89.00 price target on by analysts at BMO Capital Markets. They now have a “buy” rating on the stock.
  • 10/6/2017 – Spark Therapeutics had its “buy” rating reaffirmed by analysts at Goldman Sachs Group, Inc. (The). They now have a $111.00 price target on the stock.
  • 9/25/2017 – Spark Therapeutics had its “buy” rating reaffirmed by analysts at SunTrust Banks, Inc.. They now have a $95.00 price target on the stock, up previously from $85.00.
  • 9/14/2017 – Spark Therapeutics is now covered by analysts at Royal Bank Of Canada. They set an “outperform” rating and a $100.00 price target on the stock.
  • 9/6/2017 – Spark Therapeutics is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $104.00 price target on the stock.
  • 8/26/2017 – Spark Therapeutics was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 8/25/2017 – Spark Therapeutics had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald.
  • 8/16/2017 – Spark Therapeutics is now covered by analysts at Evercore ISI. They set an “in-line” rating and a $83.00 price target on the stock.

Shares of Spark Therapeutics, Inc. (NASDAQ ONCE) opened at 86.20 on Thursday. The stock’s market capitalization is $2.69 billion. Spark Therapeutics, Inc. has a 52-week low of $35.07 and a 52-week high of $91.00. The firm has a 50-day moving average price of $85.91 and a 200-day moving average price of $85.91.

Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share for the quarter, missing the consensus estimate of ($1.75) by ($0.14). The firm had revenue of $1.48 million for the quarter, compared to the consensus estimate of $1.33 million. Spark Therapeutics had a negative net margin of 962.72% and a negative return on equity of 59.74%. Spark Therapeutics’s quarterly revenue was up 14.7% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.04) earnings per share. On average, analysts predict that Spark Therapeutics, Inc. will post ($7.67) EPS for the current year.

In other news, insider Katherine A. High sold 5,000 shares of the stock in a transaction on Tuesday, September 26th. The stock was sold at an average price of $86.16, for a total transaction of $430,800.00. Following the transaction, the insider now directly owns 215,000 shares of the company’s stock, valued at approximately $18,524,400. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Daniel Faga sold 1,500 shares of the stock in a transaction on Tuesday, September 19th. The shares were sold at an average price of $85.00, for a total value of $127,500.00. Following the transaction, the insider now directly owns 1,500 shares in the company, valued at $127,500. The disclosure for this sale can be found here. Insiders have sold a total of 1,333,195 shares of company stock worth $109,070,506 over the last three months. Insiders own 7.30% of the company’s stock.

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Receive News & Ratings for Spark Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.